| Autor: |
Gasperi V; Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy., Savini I; Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy., Catani MV; Department of Experimental Medicine, Tor Vergata University of Rome, Rome, Italy. catani@uniroma2.it. |
| Jazyk: |
angličtina |
| Zdroj: |
Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2023; Vol. 2576, pp. 95-109. |
| DOI: |
10.1007/978-1-0716-2728-0_7 |
| Abstrakt: |
Type-1 cannabinoid receptor (CB 1 ), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both the central nervous system and peripheral tissues. Today, its biochemical identification and pharmacological characterization, as well as the screening of thousands of novel ligands that might be useful for developing CB 1 -based therapies, are the subject of intense research. Among available techniques that allow the analysis of CB 1 binding activity, radioligand-based assays represent one of the best, fast, and reliable methods.Here, we describe radioligand binding methods standardized in our laboratory to assess CB 1 binding in both tissues and cultured cells. We also report a high-throughput radioligand binding assay that allows to evaluate efficacy and potency of different compounds, which might represent the basis for the development of new drugs that target CB 1 -dependent human diseases.
(© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
